个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Lin, Gen[1,*1] ; Wang, Zhijie[2,*2] ; Chu, Qian[3] ; Hu, Yi[4] ; Huang, Dingzhi[5] ; Wang, Jun[6] ; Yang, Fan[7] ; Zhong, Wenzhao[8] ; Zhou, Chengzhi[9] ; Zhu, Bo[10] ; Ai, Xinghao[11] ; Cao, Baoshan[12] ; Cao, Yabing[13] ; Chen, Mingqiu[14] ; Chen, Xiaohui[15] ; Chu, Tianqing[16] ; Duan, Jianchun[2] ; Fan, Yun[17] ; Fang, Yong[18] ; Feng, Shuitu[19] ; Feng, Weineng[20] ; Guo, Hui[21] ; Han, Chengbo[22] ; He, Yong[23] ; Hong, Shaodong[24] ; Hu, Jie[25] ; Huang, Meijuan[26] ; Huang, Yan[24] ; Jiang, Da[27] ; Jiang, Kan[1] ; Jiang, Richeng[5] ; Jin, Bo[28] ; Jin, Shi[29] ; Li, Jisheng[30] ; Li, Min[31] ; Li, Ziming[11] ; Li, Chao[32] ; Lin, Jie[33] ; Liu, Anwen[34] ; Liu, Si-Yang Maggie[35] ; Yutao, Liu[2] ; Liu, Zhefeng[4] ; Liu, Zhe[36] ; Liu, Zhenhua[37] ; Liu, Zhentian[38] ; Liu, Zhigang[39] ; Lu, Yuping[40] ; Lv, Tangfeng[41] ; Ma, Zhiyong[42] ; Miao, Qian[1] ; Peng, Min[43] ; Pu, Xingxiang[44] ; Ren, Xiu Bao[45] ; Shan, Jianzhen[46] ; Shan, Jinlu[47] ; Shen, Peng[48] ; Shen, Bo[49] ; Shi, Meiqi[49] ; Song, Yong[41] ; Song, Zhengbo[50] ; Su, Chunxia[51] ; Sun, Jianguo[10] ; Tian, Panwen[52] ; Wang, Jinliang[4] ; Wang, Feng[15] ; Wang, Huijuan[42] ; Wang, Jialei[53] ; Wang, Qian[54] ; Wang, Wenxian[17] ; Wang, Yan[2] ; Wu, Lin[44] ; Wu, Fang[55] ; Xia, Yang[56] ; Xie, Congying[57] ; Xie, Conghua[58] ; Xin, Tao[59] ; Xiong, Jianping[60] ; Xu, Haipeng[1] ; Xu, Song[61] ; Xu, Yiquan[1] ; Xu, Bin[43] ; Xu, Chunwei[41] ; Yan, Xiaolong[62] ; Yang, Zhenzhou[63] ; Yao, Wenxiu[64] ; Yu, Yao[21] ; Feng, Ye[65] ; Yu, Zongyang[66] ; Yu, Yongfeng[11] ; Yue, Dongsheng[67] ; Zhang, Haibo[68] ; Zhang, Hongmei[69] ; Zhang, Li[3] ; Zhang, Longfeng[1] ; Zhang, Qiuyu[70] ; Zhang, Tongmei[36] ; Zhang, Bicheng[43] ; Zhao, Jun[71] ; Zhao, Mingfang[28] ; Zheng, Xiaobin[1] ; Zhong, Qiaofeng[1] ; Zhou, Jin[64] ; Zhou, Penghui[24] ; Zhu, Zhengfei[72] ; Zou, Juntao[73,74] ; Zou, Zihua[1] ;
机构： [1]Fujian Med Univ, Fujian Canc Hosp, Clin Oncol Sch, Dept Thorac Oncol, Fuzhou, Peoples R China [2]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China [3]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, Wuhan, Peoples R China [4]Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, Beijing, Peoples R China [5]Tianjin Med Univ Canc Inst & Hosp, Dept Biotherapy, Tianjin, Peoples R China [6]Shandong First Med Univ, Shandong Prov Qianfoshan Hosp, Dept Radiol, Affiliated Hosp 1, Jinan, Peoples R China [7]Peking Univ Peoples Hosp, Dept Thorac Surg, Beijing, Peoples R China [8]Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Guangzhou, Peoples R China [9]First Affiliated Hosp Guangzhou Med Univ, Guangzhou Inst Resp Hlth, Natl Clin Res Ctr Resp Dis, Natl Ctr Resp Med,State Key Lab Resp Dis,Dept Crit, Guangzhou, Peoples R China [10]Army Med Univ, Xinqiao Hosp, Inst Canc, Chongqing, Peoples R China [11]Shanghai Jiao Tong Univ, Sch Med, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China [12]Peking Univ Third Hosp, Dept Med Oncol & Radiat Sickness, Beijing, Peoples R China [13]Kiang Wu Hosp, Dept Oncol, Macau, Peoples R China [14]Fujian Med Univ, Clin Oncol Sch, Fujian Canc Hosp, Dept Radiat Oncol, Fuzhou, Peoples R China [15]Fujian Med Univ, Fujian Canc Hosp, Dept Thorac Surg, Clin Oncol Sch, Fuzhou, Peoples R China [16]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Resp Dept, Sch Med, Shanghai 200030, Peoples R China [17]Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China [18]Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Med Oncol, Hangzhou, Peoples R China [19]Fudan Univ, Dept Radiat Oncol, Xiamen branch, Shanghai Canc Ctr, Xiamen, Peoples R China [20]First Peoples Hosp Foshan, Dept Radiat Oncol, Foshan, Peoples R China [21]First Affiliated Hosp Xian Jiaotong Univ, Dept Med Oncol, Xian 710061, Peoples R China [22]Shengjing Hosp China Med Univ, Dept Oncol, Shenyang, Peoples R China [23]Army Med Univ, Xinqiao Hosp, Dept Resp Med, Chongqing, Peoples R China [24]Sun Yat sen Univ Canc Ctr, State Key Lab Oncol Southern China, Guangzhou, Peoples R China [25]Fudan Univ, Shanghai Zhongshan Hosp, Canc Ctr, Shanghai, Peoples R China [26]Sichuan Univ, West China Hosp, Canc Ctr, Div Thorac Tumor Multimodal Treatment, Chengdu, Peoples R China [27]Fourth Affiliated Hosp Hebei Med Univ, Dept Orthoped, Shijiazhuang, Herts, Peoples R China [28]First Hosp China Med Univ, Dept Med Oncol, Shenyang, Peoples R China [29]Chinese Acad Med Sci & Perking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Shenzhen 518116, Peoples R China [30]Qilu Hosp Shandong Univ, Dept Med Oncol, Jinan, Peoples R China [31]Cent South Univ, Xiangya Hosp, Dept Resp Med, Changsha, Peoples R China [32]Fujian Med Univ, Fujian Canc Hosp, Dept Pathol, Clin Oncol Sch, Fuzhou, Peoples R China [33]Second Affiliated Hosp Kunming Med Univ, Dept Hematol, Kunming, Peoples R China [34]Second Affiliated Hosp Nanchang Univ, Dept Vasc Surg, Nanchang, Peoples R China [35]Jinan Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou, Peoples R China [36]Capital Med Univ, Beijing Chest Hosp, Dept Med Oncol, Beijing, Peoples R China [37]Fujian Med Univ, Fujian Prov Hosp, Shengli Clin Med Coll, Dept Oncol, Fuzhou, Peoples R China [38]Jiangxi Canc Hosp, Dept Thorac Oncol, Nanchang, Peoples R China [39]Southern Med Univ, Affiliated Dongguan Hosp, Ctr Canc, Dongguan, Guangdong, Peoples R China [40]Fujian Med Univ, Fujian Canc Hosp, Dept Abdominal Oncol, Clin Oncol Sch, Fuzhou, Peoples R China [41]Nanjing Univ, Jinling Hosp, Dept Resp Med, Sch Med, Nanjing, Peoples R China [42]Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Dept Resp Med, Zhengzhou, Peoples R China [43]Wuhan Univ, Renmin Hosp, Wuhan, Peoples R China [44]Cent South Univ, Dept Thorac Med Oncol, Hunan Canc Hosp, Affiliated Canc Hosp,Xiangya Sch Med, Changsha, Peoples R China [45]Tianjin Med Univ, Canc Inst & Hosp, Dept Biotherapy, Tianjin, Peoples R China [46]Zhejiang Univ, Affiliated Hosp 1, Dept Nucl Med, Hangzhou, Zhejiang, Peoples R China [47]Army Med Univ, Daping Hosp, Dept Radiat Oncol, Chongqing, Peoples R China [48]Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou, Peoples R China [49]Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Inst Canc Res, Dept Med Oncol,Jiangsu Canc Hosp, Nanjing, Peoples R China [50]Zhejiang Canc Hosp, Dept Clin Trial, Hangzhou, Peoples R China [51]Tongji Univ, Shanghai Pulm Hosp, Dept Oncol, Sch Med, Shanghai, Peoples R China [52]Sichuan Univ, West China Hosp, Dept Pulm & Crit Care Med, Precis Med Key Lab Sichuan Prov,Lung Canc Ctr, Chengdu 610041, Peoples R China [53]Fudan Univ, Shanghai Canc Ctr, Dept Thorac Med Oncol, Shanghai, Peoples R China [54]Nanjing Univ Chinese Med, Affiliated Hosp, Jiangsu Prov Hosp Chinese Med, Dept Resp Med, Nanjing 210029, Peoples R China [55]Cent South Univ, Xiangya Hosp 2, Dept Oncol, Changsha, Peoples R China [56]Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Resp & Crit Care Med, Hangzhou, Peoples R China [57]Second Affiliated Hosp Wenzhou Med Univ, Wenzhou, Peoples R China [58]Wuhan Univ, Dept Hematol, Zhongnan Hosp, Wuhan, Peoples R China [59]Second Affiliated Hosp Harbin Med Univ, Dept Cardiol, Harbin, Heilongjiang, Peoples R China [60]First Affiliated Hosp Nanchang Univ, Dept Oncol, Nanchang 330006, Peoples R China [61]Tianjin Med Univ, Gen Hosp, Dept Lung Canc Surg, Tianjin, Peoples R China [62]AF Med Univ, Tangdu Hosp, Dept Thorac Surg, Xian, Peoples R China [63]Second Affiliated Hosp Chongqing Med Univ, Canc Ctr, Chongqing 400000, Peoples R China [64]Univ Elect Sci & Technol China, Sichuan Canc Hosp, Sch Med, Dept Gynecol Oncol, Chengdu, Peoples R China [65]Xiamen Univ, Dept Med Oncol, Xiamen Key Lab Antitumor Drug Transformat Res, Affiliated Hosp 1, Xiamen, Peoples R China [66]900th Hosp Joint Logist Support Force, Dept Rehabil Med, Peoples Liberat Army PLA, Fuzhou, Peoples R China [67]Tianjin Med Univ, Canc Inst & Hosp, Dept Lung Canc, Tianjin, Peoples R China [68]Guangzhou Panyu Hosp Chinese Med, Dept Oncol, Guangzhou, Peoples R China [69]Air Force Med Univ, Xijing Hosp, Dept Clin Oncol, Xian, Peoples R China [70]Fujian Med Univ, Inst Immunotherapy, Fuzhou, Peoples R China [71]Peking Univ Canc Hosp & Inst, Departmentof Thorac Oncol 1, Key Lab Carcinogenesis & Translat Res, MInist Educ, Beijing, Peoples R China [72]Fudan Univ, Shanghai Canc Ctr, Dept Radiat Oncol, Shanghai, Peoples R China [73]First Affiliated Hosp Nanchang Univ, Dept Transfus Med, Nanchang 330006, Peoples R China [74]Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr,Natl Clin Res Ctr Canc, Dept Radiat Oncol, Beijing, Peoples R China
出处：
DOI： 10.1111/1759-7714.15209
ISSN：

关键词： ICI NSCLC re-challenge

摘要：
Immune checkpoint inhibitor (ICI) rechallenge in non-small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge can be divided into three categories: adverse events (AEs); resistance to ICIs, and rechallenge becomes compulsive because of tumor relapse while the patients had completed a 2 year course of immunotherapy. However, these categories are still controversial and should be explored further. Through voting at the 6th Straits Summit Forum on Lung Cancer, in this study we summarize the consensus of 147 experts in ICI rechallenges. A total of 97.74% experts agreed to rechallenge; 48.87% experts rechallenge with the original drug, and the others rechallenge with a different drug; 40.3% agreed to rechallenge directly after progression; 88.06% experts agreed to ICI rechallenge with a combination regimen; and factors such as previous performance status score, PD-1 expression, and age should also be considered. Understanding the the clinical studies in ICI rechallenge could bring us one step closer to understanding the consensus. In patients with advanced NSCLC who have suffered recurrent or distant metastasis after immunotherapy, the option of rechallenge with ICIs is a promising treatment option.

语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 3 区 医学
小类 | 4 区 肿瘤学 4 区 呼吸系统
最新[2023]版：
大类 | 3 区 医学
小类 | 4 区 肿瘤学 4 区 呼吸系统
JCR分区：
出版当年[2023]版：
Q2 RESPIRATORY SYSTEM Q3 ONCOLOGY
最新[2023]版：
Q2 RESPIRATORY SYSTEM Q3 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Fujian Med Univ, Fujian Canc Hosp, Clin Oncol Sch, Dept Thorac Oncol, Fuzhou, Peoples R China [*1]Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
共同第一作者：
通讯作者：
通讯机构： [1]Fujian Med Univ, Fujian Canc Hosp, Clin Oncol Sch, Dept Thorac Oncol, Fuzhou, Peoples R China [2]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China [*1]Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China [*2]Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
推荐引用方式(GB/T 7714)：
Lin Gen,Wang Zhijie,Chu Qian,et al.Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer[J].THORACIC CANCER.2024,15(5):419-426.doi:10.1111/1759-7714.15209.
APA：
Lin, Gen,Wang, Zhijie,Chu, Qian,Hu, Yi,Huang, Dingzhi...&Zou, Zihua.(2024).Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.THORACIC CANCER,15,(5)
MLA：
Lin, Gen,et al."Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer".THORACIC CANCER 15..5(2024):419-426

相关文献

[1]The challenge in treating locally recurrent T3-4 nasopharyngeal carcinoma: the survival benefit and severe late toxicities of re-irradiation with intensity-modulated radiotherapy [2]Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation [3]Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation [4]中、晚期非小细胞肺癌144例用CAP、EP、IP三方案化疗疗效、毒性比较 [5]Immunotherapy for patients with advanced non-small cell lung cancer harboring oncogenic driver alterations other than EGFR: a multicenter real-world analysis [6]Patients with ASPSCR1-TFE3 fusion achieve better response to ICI based combination therapy among TFE3-rearranged renal cell carcinoma [7]Non-alcoholic fatty liver disease is associated with immune checkpoint inhibitor-based treatment response in patients with non-small cell lung cancer with liver metastases [8]Ⅳ期寡转移NSCLC同期放化疗后巩固化疗前瞻性Ⅱ期临床研究 [9]rhEPO治疗非小细胞肺癌伴贫血的效果观察 [10]非小细胞肺癌分子靶向治疗的研究进展

资源点击量：43377 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号